Tiziana Life Sciences (TLSA) Competitors $1.48 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.52 +0.04 (+3.04%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLSA vs. TRVI, ANAB, IMTX, DAWN, MRVI, AUTL, STOK, URGN, PHAT, and RLAYShould you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include Trevi Therapeutics (TRVI), AnaptysBio (ANAB), Immatics (IMTX), Day One Biopharmaceuticals (DAWN), Maravai LifeSciences (MRVI), Autolus Therapeutics (AUTL), Stoke Therapeutics (STOK), Urogen Pharma (URGN), Phathom Pharmaceuticals (PHAT), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry. Tiziana Life Sciences vs. Its Competitors Trevi Therapeutics AnaptysBio Immatics Day One Biopharmaceuticals Maravai LifeSciences Autolus Therapeutics Stoke Therapeutics Urogen Pharma Phathom Pharmaceuticals Relay Therapeutics Trevi Therapeutics (NASDAQ:TRVI) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk. Is TRVI or TLSA more profitable? Tiziana Life Sciences' return on equity of 0.00% beat Trevi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Trevi TherapeuticsN/A -58.41% -52.52% Tiziana Life Sciences N/A N/A N/A Do institutionals and insiders have more ownership in TRVI or TLSA? 95.8% of Trevi Therapeutics shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, TRVI or TLSA? Trevi Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of -0.05, indicating that its share price is 105% less volatile than the S&P 500. Do analysts rate TRVI or TLSA? Trevi Therapeutics presently has a consensus price target of $20.88, indicating a potential upside of 197.79%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Trevi Therapeutics is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.30Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation and earnings, TRVI or TLSA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevi TherapeuticsN/AN/A-$47.91M-$0.45-15.58Tiziana Life SciencesN/AN/A-$11.86MN/AN/A Does the media refer more to TRVI or TLSA? In the previous week, Tiziana Life Sciences had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 3 mentions for Tiziana Life Sciences and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.96 beat Tiziana Life Sciences' score of 0.63 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tiziana Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTrevi Therapeutics beats Tiziana Life Sciences on 7 of the 12 factors compared between the two stocks. Get Tiziana Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLSA vs. The Competition Export to ExcelMetricTiziana Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$172.94M$2.95B$5.54B$9.14BDividend YieldN/A2.43%5.01%4.00%P/E RatioN/A21.1628.6919.46Price / SalesN/A184.72373.1779.78Price / CashN/A41.0524.7227.47Price / Book37.007.758.255.58Net Income-$11.86M-$55.05M$3.19B$252.81M7 Day Performance-3.27%12.96%5.59%3.24%1 Month Performance-4.52%13.80%9.57%11.87%1 Year Performance83.17%4.53%30.64%17.60% Tiziana Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLSATiziana Life Sciences1.3564 of 5 stars$1.48flatN/A+83.2%$172.94MN/A0.008TRVITrevi Therapeutics3.9017 of 5 stars$5.95flat$20.88+250.8%+133.9%$697.89MN/A-13.2220ANABAnaptysBio1.6812 of 5 stars$23.45-1.3%$42.38+80.7%-13.0%$697.79M$91.28M-4.84100IMTXImmatics3.0975 of 5 stars$5.53-3.2%$14.67+165.2%-53.0%$694.05M$168.65M-32.53260DAWNDay One Biopharmaceuticals2.5207 of 5 stars$6.63-2.5%$30.57+361.1%-55.4%$689.27M$131.16M-9.3460MRVIMaravai LifeSciences3.6188 of 5 stars$2.60-2.6%$6.64+155.3%-69.5%$679.94M$259.18M-2.28610Positive NewsAUTLAutolus Therapeutics2.8669 of 5 stars$2.26-4.6%$9.32+312.4%-41.9%$630.76M$10.12M-2.57330Positive NewsSTOKStoke Therapeutics4.1495 of 5 stars$11.69+1.8%$23.20+98.5%-16.8%$626.77M$36.56M14.80100News CoverageURGNUrogen Pharma4.4429 of 5 stars$13.49-0.7%$32.86+143.6%-15.9%$626.14M$90.40M-4.24200PHATPhathom Pharmaceuticals4.2241 of 5 stars$8.66-2.9%$17.50+102.1%-21.2%$622.74M$55.25M-1.65110RLAYRelay Therapeutics2.5075 of 5 stars$3.55-2.2%$17.67+397.7%-56.3%$622.34M$10.01M-1.59330 Related Companies and Tools Related Companies TRVI Competitors ANAB Competitors IMTX Competitors DAWN Competitors MRVI Competitors AUTL Competitors STOK Competitors URGN Competitors PHAT Competitors RLAY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLSA) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn extra $1,000 per month?A little-known Title 15 provision could let you collect instant payouts — $100 to $1,000 — directly from your ...TradeSmith | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TLSA Stock Alerts